Jon Mattson, DO
Family Medicine · Kansas City, MONPI 1346253580
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,464 of the $53,405 with a category attached, or 68.3%. Organogenesis Inc. accounts for 97.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $19,180 and has fallen 96.7% since, to $637 in 2025. Among family medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $335.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$52K
- Mallinckrodt Hospital Products Inc.$229
- Amgen$222
- Coloplast$206
- Hydrofera LLC$157
- Musculoskeletal Transplant Foundation Inc.$149
- plus $600 from 10 others
What the payments were for
- Consulting fees$7,37514%
- Speaking & faculty fees$36,46468%
- Travel & lodging$5,50210%
- Food & beverage$4,0648%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 137 | $51,843 |
| Mallinckrodt Hospital Products Inc. | 4 | $229 |
| Amgen(2 entities) | 3 | $222 |
| Coloplast | 1 | $206 |
| Hydrofera LLC | 3 | $157 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $149 |
| Integra Lifesciences Corporation | 1 | $121 |
| Convatec Inc. | 1 | $118 |
| Melinta Therapeutics, LLC | 1 | $114 |
| AstraZeneca | 1 | $69 |
| Lilly USA, LLC | 1 | $45 |
| Novartis | 1 | $42 |
| AbbVie | 1 | $29 |
| Mimedx Group, Inc. | 1 | $25 |
| Surgenex LLC | 1 | $23 |
| Osiris Therapeutics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PuraPly$23,870
- Apligraf$17,931
- Dermagraft$12,693
- Puraply/Affinity/NuTech$12,693
- Puraply Antimicrobial$6,798
- NuShield$5,635
- Affinity$4,204
- PURAPLY WOUND MATRIX$1,397
- NOVACHOR$1,260
- SenSura Mio$206
- KRYSTEXXA$135
- OMNIGRAFT$121
- PRIMATRIX$121
- MEDIHONEY$121
- TCC-EZ$121
- AMNIOEXCEL$121
- AQUACEL Ag Advantage$118
- ConvaMax$118
- Kimyrsa$114
- HYDROFERA BLUE$106
How this compares
$53,405 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 46 | $498 |
| Mupirocin | 38 | $231 |
| Triamcinolone Acetonide | 22 | $76 |
| Prednisone | 15 | $40 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Kansas City
- Blair ThedingerKansas City$71K
- Meredith LevineKansas City$26K
- Kelly SandriKansas City$17K
- Michael SimanovskyKansas City$16K
- Teresa MarshallKansas City$16K
- Nora GomezKansas City$15K
- Julie AlvarezKansas City$15K
- Neal MooreKansas City$14K
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.